Form 4: Ventyx Biosciences CEO Granted 700,000 Stock Options

Ventyx Biosciences CEO, Raju Mohan, was granted 700,000 stock options on January 2, 2025, which vest monthly over four years.

Summary

• Raju Mohan, CEO and President of Ventyx Biosciences, was granted 700,000 stock options on January 2, 2025.
• The options have an exercise price of $2.14 per share.
• The options vest monthly over a four-year period, with 1/48th of the total shares vesting each month starting from the vesting commencement date.
• The vesting commencement date is January 2, 2025.
• The options expire on January 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative aspects to the document.

Positives

• The grant of stock options aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The stock options will vest over the next four years, subject to the CEO's continued service with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 1/48th per month is a typical vesting schedule for stock options.
• The exercise price of $2.14 is specific to Ventyx Biosciences and would need to be compared to other similar companies to determine if it is in line with industry standards.

Stakeholder Impact

• The stock option grant incentivizes the CEO to increase shareholder value.
• The vesting schedule encourages long-term commitment from the CEO.

Key Dates

Keywords

stock options, equity compensation, CEO, Ventyx Biosciences, Raju Mohan, vesting